Related Experiment Video
Updated: Jun 19, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Voxel-Based Dose-Toxicity Modeling for Predicting Post-Radiotherapy Toxicity: A Critical Perspective
1Division of Cancer Sciences, The University of Manchester, Paterson Building, Wilmslow Road, Manchester M20 4BX, UK.
None:
This perspective paper critically examines the emerging role of voxel-based analysis (VBA), also referred to as image-based data mining (IBDM), in dose-toxicity modeling for post-radiotherapy toxicity assessment. These techniques offer promising insights into localized organ subregions associated with toxicity, yet their current application faces substantial methodological and validation challenges. Based on prior studies and practical experience, we highlight seven key limitations: (i) lack of clinical validation for dose-toxicity models, (ii) strong dependence of results on statistical method selection (parametric vs. nonparametric), (iii) insensitivity of commonly used tests to uniform dose scaling, (iv) influence of tail selection (one- vs. two-tailed tests) on statistical power, (v) frequent misapplication of permutation testing, (vi) reliance on dose as the sole predictor while neglecting patient-, treatment-, and genomic-level covariates, and (vii) misinterpretation of voxel-wise associations as causal in the absence of appropriate causal inference frameworks. Collectively, these limitations can obscure clinically relevant dose differences, inflate false-positive or false-negative findings, obscure effect direction, introduce confounded associations, and ultimately yield inconsistent identification of high-risk subregions in organs at risk and poor reproducibility across studies. Notably, current univariable VBA/IBDM approaches should be regarded as hypothesis-generating rather than clinical decision-making tools, as unvalidated findings risk premature translation into clinical practice. Advancing personalized radiotherapy requires rigorous outcome validation, integration of multivariable and causal modeling strategies, and incorporation of clinical and genomic data. By moving beyond dose-only predictor models, VBA/IBDM can achieve greater biological relevance, reliability, and clinical utility, supporting more precise and individualized radiotherapy strategies.
More Related Videos
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024